

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/920,272	08/22/1997	FREDA MILLER	CIBT-P01-120 8297	
21559 75	590 02/08/2005		EXAMINER	
CLARK & EI	LBING LLP		MURPHY,	JOSEPH F
101 FEDERAL	STREET	•		
BOSTON, MA 02110			ART UNIT	PAPER NUMBER
·			1646	

DATE MAILED: 02/08/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
08/920,272	MILLER ET AL.		
Examiner	Art Unit		
Joseph F Murphy	1646		

Doioto tito t ining of any ipposit atten	Examiner	Aironic	
	Joseph F Murphy	1646	
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED <u>27 September 2004</u> FAILS TO PLACE THI	S APPLICATION IN CONDITION F	OR ALLOWANCE.	
 The reply was filed after a final rejection, but prior to filing must timely file one of the following replies: (1) an amend condition for allowance; (2) a Notice of Appeal (with appe Examination (RCE) in compliance with 37 CFR 1.114. The 	a Notice of Appeal. To avoid aband Iment, affidavit, or other evidence, val fee) in compliance with 37 CFR of e reply must be filed within one of the	donment of this applic which places the appl 41.31; or (3) a Reque	ication in st for Continued
a) The period for reply expiresmonths from the mailing			
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire l	ater than SIX MONTHS from the mailing	g date of the final rejecti	on.
Examiner Note: If box 1 is checked, check either box (a) or TWO MONTHS OF THE FINAL REJECTION. See MPEP 7	06.07(f).		
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply orig r than three months after the mailing da	of the fee. The appropr inally set in the final Offi	iate extension fee ce action; or (2) a
2. ☐ The reply was filed after the date of filing a Notice of App	eal, but prior to the date of filing an	anneal brief. The No	tice of Anneal
was filed on 19 November 2004. A brief in compliance we Notice of Appeal (37 CFR 41.37(a)), or any extension the of Appeal has been filed, any reply must be filed within the	ith 37 CFR 41.37 must be filed with ereof (37 CFR 41.37(e)), to avoid die	nin two months of the smissal of the appeal	date of filing the
AMENDMENTS			
3. The proposed amendment(s) filed after a final rejection,	•		ecause
(a) They raise new issues that would require further co	•	I E below);	
(c) They are not deemed to place the application in be	• •	ducing or simplifying	the issues for
appeal; and/or (d) ☐ They present additional claims without canceling a	corresponding number of finally rei	ected claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)).			
4. The amendments are not in compliance with 37 CFR 1.1		mpliant Amendment	(PTOL-324).
5. Applicant's reply has overcome the following rejection(s)	: the rejection under 35 USC 112 s	econd paragraph of o	laim 51.
 Newly proposed or amended claim(s) would be a non-allowable claim(s). 	llowable if submitted in a separate,	timely filed amendme	ent canceling the
 For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro 		ll be entered and an e	explanation of
The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed: Claim(s) objected to:			
Claim(s) rejected to: Claim(s) rejected: 32,33,41,42,49-52,54,55,57,58 and 60	.	•	
Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 			
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar 	overcome all rejections under appe	al and/or appellant fa	ils to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	ntry is below or attacl	ned.
 The request for reconsideration has been considered by See Attached. 	ut does NOT place the application in	n condition for allowa	nce because:
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper N	lo(s)	
13. Other:		4	
		Joseph J. W.	1
		OSEPH MURPH	1

U.S. Patent and Trademark Office PTOL-303 (Rev. 9-04) PATENT EXAMINER

11 (cont.). The amendment does not over come the rejections under 35 USC 102(b) and 103 because the claims as amended are directed to an isolated population of neural stem cells, however, Sosnowski et al teaches the establishment in primary culture of olfactory epithelium isolated from adult mouse, thus meeting the limitation that the cells are isolated. There is no limitation wherein the cells are isolated to a homogeneous population, and thus the cells of Sosnowski anticipate the claimed cells. Additionally, the Ronnette patent discloses the isolation of cells from the olfactory epithelium of neonatal rats, and their establishment in primary culture, and thus meets th limitation that the cells are isolated, and Ronnette anticipates the claims. Furthermore, the claims are unpatentable over Sosnowski et al (1995), in view of U.S. Patent No. 5,824,489 (Anderson et al.), because as set forth above, the Sosnowski reference teaches the establishment in primary culture of olfactory epithelium isolated from adult mouse, thus meeting the limitation that the cells are isolated.